Melicam

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melicam

Property Description
Active ingredient Meloxicam
Form Tablets, Oral Suspension, Injectable Solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Anti-inflammatory, Pain relief, Fever reduction
Origin Synthetic substance (Oxicam derivative)

What Type of Medicine is Melicam, and What is its Composition?

Melicam is a synthetic medicinal product containing the active ingredient Meloxicam, which is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Meloxicam is an Oxicam derivative, chemically part of the enolic acid group of substances, a classification shared by compounds like Piroxicam. This identity involves the compound's stability and systemic bioavailability. Melicam, as a single-ingredient drug, is manufactured for systemic action within the body. The drug provides flexibility through various dosage forms, including standard tablets and oral suspension, as well as a sterile injectable solution for intramuscular use, allowing for multiple routes of administration.


What is Melicam’s General Therapeutic Purpose?

The general therapeutic purpose of Melicam is to provide symptomatic relief by managing the key features of inflammatory conditions. Its use focuses on delivering an anti-inflammatory effect, analgesic effect (pain relief), and antipyretic effect (fever reduction). This benefit is achieved through the inhibition of prostaglandins. Specifically, Meloxicam is defined as a preferential COX-2 inhibitor, a characteristic that distinguishes it from older, non-selective NSAIDs. This targeted action helps alleviate discomfort and swelling by addressing and interrupting the underlying biological inflammatory process.

Regulatory References

  1. Nonsteroidal Anti-inflammatory Drug (NSAID)
  2. preferential COX-2 inhibitor

What side effects are possible with Melicam?

Melicam (meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) and, like all medications, carries risks of side effects. It is generally recommended to use the lowest effective dose for the shortest possible duration to minimize these risks.

Common Side Effects

The most frequently reported side effects are typically gastrointestinal. These may include:

  • Abdominal pain
  • Indigestion or heartburn
  • Nausea and vomiting
  • Diarrhea or constipation
  • Gas

Other common effects can be headache, dizziness, or flu-like symptoms.

Serious Safety Information and Warnings

Melicam is associated with a risk of serious, potentially life-threatening side effects, which may occur without warning. Immediate medical attention is required if any of these occur:

  • Cardiovascular Events: Increased risk of serious cardiovascular thrombotic events, including heart attack and stroke. The risk may be higher with prolonged use or in patients with pre-existing heart disease.
  • Gastrointestinal Events: Risk of serious gastrointestinal bleeding, ulceration, or perforation of the stomach or intestines. Symptoms can include severe stomach pain, black/tarry stools, or vomiting blood.
  • Hypersensitivity: Severe allergic reactions, including anaphylaxis or serious skin reactions (such as Stevens-Johnson syndrome).

Other serious risks include kidney damage, liver toxicity, increased blood pressure, and fluid retention. Patients over 65 years old and those with a history of heart, kidney, or gastrointestinal conditions are at higher risk for serious adverse effects.

Contraindications

Melicam is generally contraindicated in patients who have:

  • A known allergy or hypersensitivity to meloxicam, aspirin, or other NSAIDs.
  • Recently undergone coronary artery bypass graft (CABG) surgery.
  • A history of asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Advanced kidney disease or severe, active gastrointestinal ulceration or bleeding.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Melicam (Meloxicam) often initially presents with documented symptoms consistent with acute NSAID poisoning. These manifestations typically include lethargy, drowsiness, nausea, vomiting, and epigastric pain. The regulatory profile is clear that while these symptoms are often reversible with supportive care, serious poisoning carries a significant risk of severe organ system failure.

Life-threatening outcomes may include gastrointestinal bleeding, acute renal or hepatic dysfunction, hypertension, convulsions, coma, and potentially cardiovascular collapse or cardiac arrest.

Due to the risk of severe complications, official guidance mandates that patients seek medical attention immediately upon suspected overdose. Emergency services must be contacted if the affected person shows critical signs such as trouble breathing, collapse, or seizure activity.

There is no specific antidote known for Meloxicam. Management is strictly centered on symptomatic and supportive care. This may include the administration of activated charcoal within one to two hours of ingestion, and the use of Cholestyramine to accelerate clearance. Procedures like hemodialysis are noted as generally not useful.

Therapeutic Uses of Melicam

What Melicam Treats: Main Uses and Benefits

Melicam is commonly used to provide long-term symptomatic support for major chronic inflammatory joint diseases, including conditions where symptoms may intensify temporarily. This includes Osteoarthritis (OA) and Rheumatoid Arthritis (RA) in adults, and the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in pediatric patients. It plays a role in managing the symptoms of conditions characterized by systemic or localized discomfort, such as joint pain, swelling, and physical stiffness. The therapeutic benefit is focused on providing support that helps ease the overall symptom burden and assists with maintaining functional stability.


The medication is also considered relevant in contexts where additional symptomatic support is needed for acute, moderate-to-severe pain and associated localized inflammation. It is commonly applied in clinical settings for post-operative pain management or during other situations requiring short-term symptom stabilization. The indications primarily target persistent conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, in addition to specific acute pain needs.


Quick Fact: Relief for Inflammation and Discomfort

Melicam is applied across domains where symptoms related to systemic imbalance, such as fever, accompany the primary inflammatory condition. It supports the patient during difficult episodes by easing distress by providing an antipyretic effect, which may be part of symptomatic management. This helps address the symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Melicam?

The regulatory profile for Melicam (Meloxicam) defines strict criteria for eligibility based on age, pre-existing conditions, and physiological state.

Contraindicated Populations (Must Not Use)

Melicam is absolutely contraindicated in patients with a known hypersensitivity to Meloxicam, or a history of asthma, urticaria, or allergic reactions after taking Aspirin or other NSAIDs.

Contraindications also apply to:

  • Patients in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Patients with active gastrointestinal bleeding or recurrent peptic ulceration.
  • Patients with severe uncontrolled heart failure or severe, non-dialyzed hepatic or renal failure.
  • Women who are 30 weeks pregnant or later.

Age-Related and Restricted Use

  • Children under 2 years of age are contraindicated.
  • Use is established for adults (e.g., Osteoarthritis/RA) and for pediatric patients ge 2 years for Juvenile Idiopathic Arthritis (JIA). Use for other pediatric indications is not established.
  • Older adults are recognized as being at higher risk for serious GI and renal adverse reactions, requiring special caution.
  • Use is not recommended for women who are nursing or in the early stages of pregnancy (prior to 30 weeks gestation).

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Melicam (Meloxicam) is formally defined by regulatory authorities based on pharmacokinetic and pharmacodynamic outcomes. Co-administration is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. The use of Melicam with other non-Aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is generally not recommended due to the officially documented increased risk of gastrointestinal adverse events.

Several combinations carry an additive risk of bleeding and ulceration, including co-administration with oral anticoagulants (such as Warfarin), antiplatelet agents (including low-dose Aspirin), oral corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs). Furthermore, Melicam may diminish the officially documented effect of antihypertensive agents, including ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and diuretics. This combination, particularly in elderly or volume-depleted patients, is noted to increase the risk of deterioration of renal function.

Pharmacokinetic interactions exist where Melicam may increase the plasma concentrations of certain co-administered drugs, such as Lithium and Methotrexate, by reducing their renal clearance. Conversely, Cholestyramine officially documents a reduction in Melicam exposure (AUC) by interrupting its enterohepatic recirculation. Melicam tablets can be administered without mandatory timing separation from meals or antacids.

Mechanism of Action

Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), functions primarily as a preferential inhibitor of the enzyme cyclooxygenase-2 (COX-2).

Meloxicam binds to the active site of the COX-2 isozyme, competing with the physiological substrate, arachidonic acid. This interaction structurally restricts the enzyme's capacity to catalyze the initial committed step in eicosanoid biosynthesis. The resultant molecular pathway interruption leads to a dose-dependent reduction in the intracellular synthesis of prostaglandins and thromboxanes, which are derived from the upstream arachidonic acid cascade.

Downstream, the decreased concentration of these lipid mediators results in a systemic modulation of the inflammatory response at the cellular level. Specifically, reduced prostaglandin E2 ( PGE2) production mitigates the sensitization of peripheral nociceptors and attenuates vascular permeability changes. The overall system-level physiological consequence is a reduction in the biological processes that define localized and systemic inflammatory states.

Dosage and Administration Information

Administration Guidelines for Melicam (Meloxicam)

Melicam is administered using specific patterns focusing on defined routes, dosing ceilings, and frequency.


Administration Scope

Instruction Detail
Route of Administration Oral (tablets and oral suspension) and Intravenous (IV) (for injection).
Labeled Dosing Regimen Adult oral dose starts at 7.5 mg once daily, with a maximum established at 15 mg once daily for all approved indications. The IV dose is 30 mg once daily.
Dosing Frequency The medicine is administered once daily for both oral and intravenous forms.
Timing and Preparation Oral forms may be taken with or without food. Oral suspension must be shaken well prior to administration.

Population-Specific and Procedural Constraints

Dose restrictions apply for certain populations, such as a maximum daily dosage of 7.5 mg for patients undergoing hemodialysis. For Juvenile Rheumatoid Arthritis (JRA), the maximum dose is also limited to 7.5 mg once daily. The intravenous formulation, available in a 30 mg/mL strength, is administered as an IV bolus injection delivered over a period of 15 seconds.


Connection to the Overall Use Protocol

These guidelines establish the procedural structure for using Melicam by defining the dosage ceiling and the once daily frequency for all routes. The usage protocol is centered on the principle that the medicine is used at the lowest effective dose for the shortest duration to manage symptoms, with oral use supporting long-term conditions and IV use reserved for acute, short-term management.

Recent Clinical Evidence

Research evidence / Overview of studies for Melicam

Research Evidence for Chronic Inflammatory Joint Conditions

The research base for Melicam includes studies for long-term joint conditions, built upon multiple Randomized Controlled Trials (RCTs) and peer-reviewed meta-analyses. These studies explored how symptoms change over time in adults diagnosed with Osteoarthritis (OA) and Ankylosing Spondylitis (AS). For OA, research examined outcomes related to physical discomfort and daily functioning. Findings describe patterns observed where patients reported changes in pain intensity and functional scores over periods typically up to six months. However, the long-term outcomes and the durability of reported changes beyond one year are not fully established by the core RCT data.

Evidence for Rheumatoid Arthritis (RA) and Special Age Groups

For adults with active Rheumatoid Arthritis (RA), the evidence is derived from studies that tracked patient-reported outcomes using composite measures, such as the ACR 20 response criteria. The studies report how symptoms evolved in the observed populations, with many patients monitored in long-term extension studies for up to 18 months. Research does not determine whether an individual will respond similarly, and studies were not designed to examine whether the medicine prevents the progression of joint damage.

Research has also explored use in children aged two and older with Juvenile Rheumatoid Arthritis (JRA). Dedicated Phase I and II research was conducted to define the relationship between dose and systemic exposure for this age group, using specialized outcomes like the ACR Pediatric 30% Improvement Criteria. Due to the nature of pediatric research, the sample sizes were modest compared to adult trials, and there is limited information for long-term outcomes spanning multiple years.

Key Studies & References

  1. Meloxicam: MedlinePlus Drug Information (Uses, Dosage, and Indications)
  2. Clinical Trials for Meloxicam in Juvenile Rheumatoid Arthritis (JRA/JIA) - Study NCT00279747

Frequently Asked Questions (FAQ)

Common questions about Melicam (FAQ)


Q: How quickly does Melicam usually start to work?

Official product information suggests that some pain relief may be noted within hours of administration. However, the full anti-inflammatory effects of the medicine may require one to two weeks of therapy to develop completely.


Q: Can Melicam be taken for headaches or menstrual cramps?

Regulatory documents describe Melicam's use for the relief of signs and symptoms related to Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA). The official labeling does not formally list the medicine for the treatment of headaches or menstrual cramps.


Q: What kind of pain is Melicam typically prescribed for?

Melicam is described in official documents as indicated for the relief of signs and symptoms related to chronic inflammatory joint conditions. These conditions include Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA). Its purpose is to provide both pain relief (analgesic) and anti-inflammatory effects.


Q: Does Melicam cause drowsiness or make you tired?

Drowsiness is not commonly listed as a typical side effect in the primary clinical data. Official safety information does note that it is a potential risk of overdose.


Q: Are there any foods or drinks to avoid while taking Melicam?

Official product information notes that alcohol increases the risk of gastrointestinal irritation and bleeding when combined with Melicam. Some regulatory information indicates caution regarding grapefruit juice, as it may potentially increase the medicine’s exposure in the body.


Q: Is Melicam safe for long-term use?

Official regulatory guidance emphasizes that the medicine should be used at the lowest effective dose for the shortest duration consistent with treatment goals. Due to the potential for serious adverse effects, long-term use necessitates periodic monitoring of kidney and liver function as described in the prescribing information.


Q: What happens if I forget to take a dose of Melicam?

Official patient information typically suggests that if a dose is missed but the next scheduled dose is approaching, the missed dose should be passed over. The protocol indicates that a double dose is not to be taken to compensate for a missed dose.


Q: Does Melicam interact with common over-the-counter cold medicines?

Official warnings note that combining Melicam with other non-Aspirin NSAIDs may increase risk. Regulatory documents also indicate caution regarding products that contain sympathomimetic agents (a type of stimulant) due to the potential for cardiovascular effects.


Q: How long do the effects of Melicam last?

The pharmacological characteristic of Melicam, as described in official sources, includes a duration of action of approximately 24 hours. This supports the established once-daily dosing frequency.


Q: Does Melicam affect blood pressure or heart rate?

Official documents state that the medicine may increase or worsen blood pressure. The risk of serious cardiovascular thrombotic events (like heart attack or stroke) is also noted in regulatory information.


Q: Why does Melicam sometimes have a Black Box Warning?

Regulatory agencies require the most serious warnings (known as Boxed Warnings in the U.S.) due to the increased risk of serious cardiovascular thrombotic events (including heart attack and stroke) and serious gastrointestinal adverse events (including bleeding, ulceration, and perforation). These warnings draw attention to potentially life-threatening risks.


Q: Can Melicam be crushed or chewed?

Melicam tablets are described in official patient information as the form intended to be swallowed whole with water. Regulatory documentation provides limited information on the effects or safety profile related to crushing or chewing the tablets or mixing them with food or fluids.


Q: What is the difference between prescription and over-the-counter versions of this drug class?

The active ingredient, meloxicam, is generally a prescription-only medication. The differences between NSAIDs can relate to dose strength and a medication’s degree of selectivity for COX-2 inhibition, which Melicam is described as having preferentially.


Q: Can I drive while taking Melicam?

Official safety documents list dizziness as a common side effect and note the potential for visual disturbances or somnolence (drowsiness). These effects may impair a person’s ability to drive or operate machinery.


Q: What if I take Melicam too close to my next dose time?

Because Melicam has an established once-daily administration frequency, regulatory guidance describes a protocol where taking doses too close together may increase the risk of adverse effects. The protocol typically states that if a dose is missed and the time for the next dose is near, the missed dose is omitted.


Q: Are there any known interactions between Melicam and vitamins or supplements?

Official regulatory documents indicate that the medicine may interact with some supplements. For instance, Melicam may increase blood potassium levels when used with certain potassium supplements.


Q: Why do official documents mention heart-related risks with Melicam?

Official documents note an increased risk of serious cardiovascular thrombotic events due to the nature of the medication's effects. These events include myocardial infarction (heart attack) and stroke, which can be fatal.


Q: Does Melicam affect birth control pills?

The official interaction profile indicates that Melicam may increase blood potassium levels when used with some hormonal contraceptives containing the ingredient drospirenone.


Q: How does Melicam relieve pain compared to just Tylenol (acetaminophen)?

Melicam is an NSAID that is defined by regulatory bodies as having both pain-relieving (analgesic) and anti-inflammatory effects. In contrast, acetaminophen (Tylenol) is primarily an analgesic that lowers fever and relieves pain without providing significant anti-inflammatory effects.


Q: Can Melicam cause changes in mood or behavior?

Changes in mood or behavior have been reported in post-marketing data, though the frequency is not known according to the official product information. These types of effects are not typically listed among the most common adverse reactions.


Q: What is the reason Melicam is contraindicated for people with specific stomach conditions?

The official Black Box Warning explains that NSAIDs increase the risk of serious gastrointestinal adverse events. These events include bleeding, ulceration, and perforation of the stomach or intestines, which is why the drug is contraindicated in active GI conditions.


Q: Does Melicam show up on drug tests?

According to official information on drug screenings, Meloxicam (the active ingredient in Melicam) is not typically included in standard drug tests. Such tests are usually focused on detecting controlled substances.


Q: Are there any specific laboratory tests required while taking Melicam?

For patients using Melicam for long-term therapy, prescribing information indicates the necessity of periodic laboratory tests. These tests are used to monitor key parameters, including kidney function, liver function, and complete blood counts.


Q: Do I need to stop taking Melicam before surgery?

Official documents state that the medicine is contraindicated (use is prohibited) in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery. General guidance regarding cessation before other surgical procedures is not uniformly defined in regulatory labeling.


Q: What research is currently being done on Melicam or similar compounds?

Regulatory documents frequently note ongoing pharmacological research focused on understanding the drug’s metabolism. This includes studies on how Melicam is processed by liver enzymes like CYP2C9 and CYP3A4 and its effects on specific patient populations.


Q: What is the maximum duration for using Melicam as described by regulatory agencies?

Regulatory guidance emphasizes the use of the lowest effective dose for the shortest duration consistent with treatment goals. A specific, quantified time limit (e.g., a number of days) for the duration of chronic use is not provided in the primary documents.


Q: Are generic versions of Melicam considered equivalent?

The active ingredient, meloxicam, is marketed by many companies as a generic drug. Regulatory agencies approve these generic versions based on studies demonstrating their bioequivalence to the original branded product.


Q: What are the signs of taking too much Melicam?

Signs of taking too much Melicam, or toxicity, can include severe symptoms such as vomiting and diarrhea, extreme dizziness and confusion, or signs of liver or kidney failure. Loss of consciousness can also occur.


Q: Does Melicam interact with common herbal supplements like St. John's Wort?

Regulatory documents indicate that Melicam may interact with some herbal supplements. For example, co-administration with supplements like ginkgo may further increase the documented risk of bleeding.

How should Melicam be stored and disposed of?

How to Store and Dispose of Meloxicam (Melicam) Tablets

Meloxicam tablets must be stored at Controlled Room Temperature, which is defined by regulatory bodies as 20 to 25 C (68 to 77 F). The medicine must be kept in a dry place and dispensed in a tight container to maintain product stability and protect it from excessive heat and moisture.

Child Safety and Disposal

All medications, including Meloxicam, must be stored out of the sight and reach of children.

To dispose of unused or expired Meloxicam, follow local pharmaceutical waste collection procedures. Regulatory guidance states that the medicine should not be disposed of via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melicam found in:

A-Z Index: